Loading
A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting.
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC is a phase 3 interventional study registered as NCT04821622 by Pfizer, with 599 participants enrolled, started 2021-05-12 and due to reach its primary completion in 2026-02-18. Interventions recorded: talazoparib plus enzalutamide and Placebo plus enzalutamide.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, PARP inhibitors, Prostate cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.
Shares Astellas, Pfizer (incl. Seagen) and the tag pipeline.